Soligenix sets up consortium to develop thermostable vaccines
This article was originally published in Scrip
Executive Summary
Soligenix of the US, formerly known as DOR BioPharma, has established a consortium to develop thermostable technology to advance its RiVax vaccine and other rapidly acting vaccines. The consortium will be funded by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the US National Institutes of Health (NIH).